Sales & Marketing News | pharmaphorum

News

GLP-1s drive Lilly's Q1, but it's reticent on oral launch

Investors are itching for news on the rollout of Lilly's oral weight-loss drug Foundayo, but there's little information in its first-quarter update.

News

Norgine gets first EU approval for WHIM syndrome therapy

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

News

AZ will invest £300m in UK, says PM Keir Starmer

AstraZeneca has delivered a much-needed boost to the UK government alongside a strong set of first-quarter results.

News

First-quarter sales strength buoys new GSK CEO Miels

GSK has had a solid start to 2026, with revenues rising ahead of analyst expectations in the first full quarter under new CEO Luke Miels.

News

GSK eyes October FDA verdict on chronic hep B drug

GSK's antisense-based drug for chronic hepatitis B (CHB), bepirovirsen, has started a speedy FDA review that should deliver a verdict by 26th October.

GLP-1s drive Lilly's Q1, but it's reticent on oral launch

Norgine gets first EU approval for WHIM syndrome therapy

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

AZ will invest £300m in UK, says PM Keir Starmer

First-quarter sales strength buoys new GSK CEO Miels

GSK eyes October FDA verdict on chronic hep B drug

Parexel buys Vitrana to boost patient safety toolkit

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks